Key result
RAS blockade offers a promising clinical strategy for treating gynecologic cancers.
Why the study?
The role of the renin-angiotensin system in the progression of gynecologic cancers and the therapeutic potential of its blockade were not fully elucidated.
Does blockade of the renin-angiotensin system (RAS) reduce tumor progression in gynecologic cancers?
Does blockade of the renin-angiotensin system (RAS) reduce tumor progression in gynecologic cancers?
Blocking the renin-angiotensin system may represent a novel therapeutic strategy for treating gynecologic cancers by inhibiting tumor growth and angiogenesis.
Hypothesis-generating for RAS blockade in gynecologic cancers; should not yet change practice without randomized trials.
No abstract yet. The journal hasn't published one we can show.
No takes yet. Share an insight, caveat, or question.
Ino et al. (2011) conducted a review in Gynecologic cancers. Renin-angiotensin system (RAS) blockade was evaluated. Blocking the renin-angiotensin system presents a novel and promising clinical strategy for the treatment of gynecologic cancers, including cervical, endometrial, and ovarian cancers.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: